Fax (011) 39 02 2643 7298
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy†
Article first published online: 1 MAR 2011
DOI: 10.1002/cncr.25985
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Salonia, A., Gallina, A., Briganti, A., Abdollah, F., Suardi, N., Capitanio, U., Colombo, R., Freschi, M., Rigatti, P. and Montorsi, F. (2011), Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer, 117: 3953–3962. doi: 10.1002/cncr.25985
- †
The authors thank Dragonfly Editorial for reviewing the language in the manuscript.
- ‡
Fax (011) 39 02 2643 7298
Publication History
- Issue published online: 19 AUG 2011
- Article first published online: 1 MAR 2011
- Manuscript Accepted: 4 NOV 2010
- Manuscript Revised: 3 NOV 2010
- Manuscript Received: 29 JUN 2010
REFERENCES
- 1, , , et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol. 2004; 92: 221-236.
- 2, , , et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res. 2005; 65: 300-308.
- 3, , , et al. Hypogonadism in male patients with cancer. Cancer. 2006; 106: 2583-2591.
- 4, , , et al. Androgens and prostate cancer risk: a prospective study. Prostate. 2007; 67: 1230-1237.
- 5, , , et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008; 122: 2345-2350.
- 6, , , et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009; 56: 48-56.
- 7, , , et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999; 86: 312-315.
- 8, , , et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1262-1269.
- 9, Prostate Cancer Collaborative Group, , , , . Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100: 170-183.
- 10, , , , , . Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009; 73: 356-361.
- 11. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009; 181: 972-979.
- 12, . Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006; 68: 1263-1267.
- 13, , , . Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006; 175: 1341-1345.
- 14, , , et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 2007; 67: 9089-9096.
- 15, , , et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169: 1670-1675.
- 16, , , et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005; 47: 308-312.
- 17, , , , , . Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173: 1935-1937.
- 18, , , , , . Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005; 174: 2178-2180.
- 19, , , et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 86-91.
- 20, , , et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res. 2008; 28: 2487-2492.
- 21, , . American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
- 22How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory; Approved Guidelines. Villanova, PA: National Committee for Clinical Laboratory Standards; 1995.
- 23, , , et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69: 1095-1101.
- 24American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002; 8: 440-456.
- 25, , , et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89: 5916-5919.
- 26, , , et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95: 1810-1818.
- 27, , , et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009; 55: 121-130.
- 28, , , et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health across the Nation. J Clin Endocrinol Metab. 2005; 90: 4836-4845.
- 29. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol. 2007; 52: 623-625.
- 30, , , , , . Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010; 105: 884-885.
- 31, , , . No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol. 2002; 168: 1188-1192.
- 32, , . Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000; 163: 824-827.
- 33, , , et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001; 47: 52-58.
- 34, , , et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer. 2007; 121: 791-795.
- 35, , , et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439-445.
- 36, , , et al. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009; 182: 491-496.
- 37, , . A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666-3672.
- 38, , , et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. 2006; 99: 182-188.
- 39, , , et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett. 2007; 28: 45-51.
- 40, , , , . Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr. 1997; 156: 7-14.
- 41, , , et al. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol. 2008; 15: 472-480.
- 42, , , et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998; 160: 449-453.
- 43, , , . Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand J Urol Nephrol. 1980; 14: 225-227.
- 44, , , et al. Serum inhibin–not a cause of low testosterone levels in hypogonadal prostate cancer? Urology. 2008; 72: 1121-1124.
- 45, , , , , . Elevated expression of inhibin alpha in prostate cancer. J Urol. 2004; 171: 192-196.
- 46, , , et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010; 70: 1256-1264.
- 47, , , et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids. 2007; 72: 375-380.
- 48, , , et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007; 67: 5033-5041.
- 49, , , , , . Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10: 301-306.
- 50, , , et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol. 2007; 52: 733-743.